Abstract:To investigate the fluorescein angiography (FA) findings and compare the extent of retinal vascularization in retinopathy of prematurity (ROP), recovered after intravitreal ranibizumab (IVR) monotherapy and those regressed spontaneously. Infants with a history of ROP who underwent FA between April 2018 and November 2021 were retrospectively included. The patients were divided into two groups based on whether they had received IVR (IVR group) or had ROP that regressed spontaneously without treatment (untreated group). The differences between the two groups in zone II ROP were also compared, to equalize the subgroups as much as possible in terms of disease severity. FA findings were recorded. The extent of vascularization was measured by the ratio of the distance from the center of the disk to the border of the vascularized zone (DB) and the distance from the center of the disk to the center of the fovea (DF). The width of the persistent avascular retina (PAR) was counted by disc diameters (DD). One hundred and ten eyes of 55 infants were included in the IVR group and 76 eyes of 38 babies in the untreated group. The ratio of abnormal shape of vessels was significantly higher in the IVR group than in the untreated group (50.9% vs. 35.5%; P = 0.038), while the linear choroidal filling pattern, tortuosity of vessels over the posterior pole, dye leakage, anomalous branching of vessels, circumferential vessels, arteriovenous shunt, abnormal capillary bed, and macular abnormalities were similarly. There was a smaller temporal DB/DF ratio (4.48 vs. 4.63; P = 0.003) and greater PAR (2.63 vs. 1.76; P < 0.001) in the IVR group compared to the untreated group. In zone II ROP, the progression of retinal vascularization was significantly larger in the IVR group than that in the untreated group ( P = 0.003), while no statistical differences were observed in FA features, the DB/DF ratio, and PAR between the two subgroups. The residual vascular abnormalities and PAR may be common results of ROP regression. The DB/DF ratio of 4.0 temporally and 3.3 nasally could be used as the preliminary indicators for safe retinal vascularization in the completion of ROP regression.

Characteristics of ‘sawtooth shunt’ following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity

Long-term surgical outcomes and prognostic factors for advanced-stage retinopathy of prematurity after vitrectomy

Evaluation of Retinal Vascularization in Retinopathy of Prematurity Regressed after Intravitreal Ranibizumab Monotherapy or Without Treatment Based on Fluorescein Angiography

Clinical Characteristics and Treatment Outcomes of Aggressive Posterior Retinopathy of Prematurity

Anti-vascular endothelial growth factor treatment for retinopathy of prematurity

The Analysis of Foveal Microvascular Anomalies in Retinopathy of Prematurity after Anti-Vascular Endothelial Growth Factor Therapy Using Optical Coherence Tomography Angiography

A pilot optical coherence tomography angiography classification of retinal neovascularization in retinopathy of prematurity

Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF)

Non-surgical treatment of stage 4A retinopathy of prematurity

Application by Intravitreal and Topical Instillation

Outcome of eyes treated for Retinopathy of Prematurity in Posterior Zone I: An Eastern India study.

Vascular development analysis: a study for tertiary anti-vascular endothelial growth factor therapy after second reactivation of retinopathy of prematurity

Expression of Total Vascular Endothelial Growth Factor and the Anti-angiogenic VEGF 165 B Isoform in the Vitreous of Patients with Retinopathy of Prematurity.

Laser versus Anti-VEGF: A Paradigm Shift for Treatment-Warranted Retinopathy of Prematurity

Foveal Structure Changes in Infants Treated with Anti-Vegf Therapy or Laser Therapy Guided by Optical Coherence Tomography Angiography for Retinopathy of Prematurity.

Clinical effect of laser photocoagulation combined with minimal doses of intravitreal Ranibizumab for aggressive posterior retinopathy of prematurity

Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment

Fluorescein Angiography Of Retinal Vascular Involution After Intravitreal Injection Of Ranibizumab For Retinopathy Of Prematurity

Spectral optical coherence tomography-angiography for structural and microcirculatory retinal disorders assessment in aggressive posterior retinopathy of prematurity

Outcomes and Prognostic Factors for Aggressive Posterior Retinopathy of Prematurity Following Initial Treatment with Intravitreal Ranibizumab

Recent advances in foveal development after treatment for retinopathy of prematurity